XML 26 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Cash Flows - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Cash Flows From Operating Activities      
Net income (loss) $ 18,779,000 $ (47,896,000) $ (42,603,000)
Adjustments to reconcile net income (loss) to net cash and cash equivalents provided by (used in) operating activities:      
Stock-based compensation 20,652,000 14,599,000 10,489,000
Deferred taxes (11,740,000) (15,253,000) (16,754,000)
Depreciation and amortization 59,791,000 59,653,000 47,252,000
Acquired in-process research and development ("IPR&D") 0 1,151,000 0
Non-cash operating lease expense 1,269,000 0 0
Non-cash interest 3,922,000 3,961,000 2,512,000
Contingent consideration fair value adjustment 1,426,000 4,058,000 500,000
Loss on extinguishment of debt 0 0 1,458,000
Asset impairment charges 0 574,000 2,374,000
Gain on sale of ANDAs 0 (750,000) (1,822,000)
Changes in operating assets and liabilities, net of acquisition (2021):      
Accounts receivable, net 3,359,000 (36,912,000) (5,548,000)
Inventories (5,841,000) (23,626,000) 3,224,000
Prepaid expenses and other current assets (9,015,000) (798,000) 127,000
Accounts payable 7,552,000 5,038,000 10,166,000
Accrued royalties 6,969,000 3,082,000 (267,000)
Current income taxes payable, net 11,991,000 (160,000) (7,573,000)
Accrued government rebates 1,296,000 5,380,000 (3,078,000)
Returned goods reserve (3,722,000) (2,399,000) 6,503,000
Accrued expenses, accrued compensation, and other 12,271,000 (905,000) (3,638,000)
Net Cash and Cash Equivalents Provided by (Used in) Operating Activities 118,959,000 (31,203,000) 3,322,000
Cash Flows From Investing Activities      
Acquisition of Novitium Pharma LLC, net of cash acquired 0 (33,000) (84,494,000)
Acquisition of product rights, IPR&D, and other related assets (9,643,000) (7,579,000) (21,081,000)
Acquisition of property and equipment, net (8,868,000) (8,876,000) (2,557,000)
Proceeds from the sale of long-lived assets 0 750,000 2,649,000
Net Cash and Cash Equivalents Used in Investing Activities (18,511,000) (15,738,000) (105,483,000)
Cash Flows From Financing Activities      
Proceeds from public offering, net of transaction expenses 80,555,000 0 69,584,000
Payments on contingent consideration (12,500,000) 0 0
Payments on Term Loan and Delayed Draw Term Loan agreements 0 0 (10,862,000)
Payments on borrowings under credit agreements (3,000,000) (3,000,000) 0
Borrowings under Prior Revolver agreement 0 0 24,000,000
Repayment of Prior Credit Facility 0 0 (200,148,000)
Borrowings under the Credit Facility, net of issuance costs 0 0 286,032,000
Proceeds from issuance of convertible preferred stock 0 0 25,000,000
Series A convertible preferred stock dividends paid (1,625,000) (1,625,000) (190,000)
Proceeds from stock option exercises and ESPP purchases 8,996,000 1,458,000 2,069,000
Treasury stock purchases for restricted stock vests (4,987,000) (1,959,000) (890,000)
Net Cash and Cash Equivalents Provided by (Used in) Financing Activities 67,439,000 (5,126,000) 194,595,000
Net Change in Cash and Cash Equivalents 167,887,000 (52,067,000) 92,434,000
Cash and cash equivalents, beginning of year 53,234,000 105,301,000 12,867,000
Cash and cash equivalents, end of year 221,121,000 53,234,000 105,301,000
Reconciliation of cash, cash equivalents, and restricted cash, beginning of year      
Cash and cash equivalents 221,121,000 48,228,000 100,300,000
Restricted cash 0 5,006,000 5,001,000
Total cash, cash equivalents, and restricted cash 221,121,000 53,234,000 105,301,000
Supplemental disclosure for cash flow information:      
Cash paid for interest, net of amounts capitalized 31,431,000 21,477,000 9,705,000
Cash paid for income taxes 1,228,000 288,000 10,371,000
Right-of-use assets obtained in exchange for lease obligations 4,715,000 0 0
Supplemental non-cash investing and financing activities:      
Fair value of contingent consideration in a business combination 0 0 30,500,000
Fair value of equity issued as consideration in a business combination 0 0 91,199,000
Acquisition of product rights included in accounts payable 0 1,000,000 0
Property and equipment purchased and included in accounts payable $ 328,000 $ 452,000 $ 152,000